These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1650667)

  • 1. Bromovinyldeoxyuridine treatment of herpetic keratitis clinically resistant to other antiviral agents.
    Maudgal PC; De Clercq E
    Curr Eye Res; 1991; 10 Suppl():193-9. PubMed ID: 1650667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bromovinyldeoxyuridine (BVDU) and trifluorothymidine (TFT) in dendritic corneal ulceration: a double blind controlled study.
    Power WJ; Benedict-Smith A; Hillery M; Brady K; Collum LM
    Curr Eye Res; 1991; 10 Suppl():183-7. PubMed ID: 1907535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of (E)-5-(2-bromovinyl)-2'-deoxyuridine in the topical treatment of herpes simplex keratitis.
    Maudgal PC; Missotten L; De Clercq E; Descamps J; De Meuter E
    Albrecht Von Graefes Arch Klin Exp Ophthalmol; 1981; 216(4):261-8. PubMed ID: 7020469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experimental stroma herpes simplex keratitis. Influence of treatment with topical bromovinyldeoxyuridine and trifluridine.
    Maudgal PC; De Clercq E; Descamps J; Missotten L; Wijnhoven J
    Arch Ophthalmol; 1982 Apr; 100(4):653-6. PubMed ID: 6803747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomised double-blind trial of bromovinyldeoxyuridine (BVDU) and trifluorothymidine (TFT) in dendritic corneal ulceration.
    Power WJ; Benedict-Smith A; Hillery M; Brady K; Collum LM
    Br J Ophthalmol; 1991 Nov; 75(11):649-51. PubMed ID: 1751456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of bromovinyldeoxyuridine in the treatment of herpes simplex virus and varicella-zoster virus eye infections.
    Maudgal PC; De Clercq E; Missotten L
    Antiviral Res; 1984 Oct; 4(5):281-91. PubMed ID: 6335020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bromovinyldeoxyuridine and interferon treatment in ulcerative herpetic keratitis: a double masked study.
    van Bijsterveld OP; Meurs PJ; de Clercq E; Maudgal PC
    Br J Ophthalmol; 1989 Aug; 73(8):604-7. PubMed ID: 2669938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (E)-5-(2-bromovinyl)-2'-Deoxyuridine in the treatment of experimental herpes simplex keratitis.
    Maudgal PC; De Clercq E; Descamps J; Missotten L; De Somer P; Busson R; Vanderhaeghe H; Verhelst G; Walker RT; Jones AS
    Antimicrob Agents Chemother; 1980 Jan; 17(1):8-12. PubMed ID: 7352751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Herpetic keratitis. Proctor Lecture.
    Kaufman HE
    Invest Ophthalmol Vis Sci; 1978 Oct; 17(10):941-57. PubMed ID: 100465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ac2IDU, BVDU, and thymine arabinoside therapy in experimental herpes keratitis.
    Hettinger ME; Pavan-Langston D; Park NH; Albert DM; De Clercq E; Lin TS
    Arch Ophthalmol; 1981 Sep; 99(9):1618-21. PubMed ID: 7283815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of 9-(2-phosphonylmethoxyethyl)adenine in the therapy of TK+ and TK- herpes simplex virus experimental keratitis.
    Maudgal PC; De Clercq E
    Curr Eye Res; 1991; 10 Suppl():139-42. PubMed ID: 1650660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral antiviral drugs in experimental herpes simplex keratitis.
    Kaufman HE; Varnell ED; Centifanto-Fitzgerald YM; De Clercq E; Kissling GE
    Antimicrob Agents Chemother; 1983 Dec; 24(6):888-91. PubMed ID: 6318664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vidarabine therapy of complicated herpes simplex keratitis.
    O'Day DM; Poirier RH; Jones DB; Elliott JH
    Am J Ophthalmol; 1976 May; 81(5):642-9. PubMed ID: 1275044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical resistance of herpetic keratitis to antiviral agents (author's transl)].
    Colin J; Chastel C; Baikoff G; Renard G
    J Fr Ophtalmol; 1981; 4(1):57-60. PubMed ID: 6260850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental thymidine kinase-deficient HSV-1 keratitis: therapeutic attempts.
    Maudgal PC; De Clercq E; Huyghe P
    Curr Eye Res; 1987 Apr; 6(4):579-84. PubMed ID: 2953558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of bromovinyldeoxyuridine-related compounds in the treatment of experimental herpes simplex keratitis.
    Maudgal PC; De Clercq E
    Arch Ophthalmol; 1985 Sep; 103(9):1393-7. PubMed ID: 4038133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine in the therapy of thymidine kinase-positive and -deficient herpes simplex virus experimental keratitis.
    Maudgal PC; De Clercq E
    Invest Ophthalmol Vis Sci; 1991 May; 32(6):1816-20. PubMed ID: 1851733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative evaluation of BVDU ((E)-5-(2-bromovinyl)-2'-deoxyuridine) in the treatment of experimental herpes simplex keratitis in rabbits.
    Maudgal PC; De Clercq E; Descamps J; Missotten L
    Bull Soc Belge Ophtalmol; 1979; 186():109-18. PubMed ID: 554711
    [No Abstract]   [Full Text] [Related]  

  • 19. [BVDU therapy in herpes corneae].
    Benad A; Richter E
    Klin Monbl Augenheilkd; 1989 Jun; 194(6):424-6. PubMed ID: 2761189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic indicators of herpetic keratitis. Analysis of a five-year observation period after corneal ulceration.
    Wilhelmus KR; Coster DJ; Donovan HC; Falcon MG; Jones BR
    Arch Ophthalmol; 1981 Sep; 99(9):1578-82. PubMed ID: 6793030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.